DermTech Ret. em ativos

Qual é o Ret. em ativos de DermTech?

O Ret. em ativos de DermTech, Inc. é -68.96%

Qual é a definição de Ret. em ativos?



Retorno sobre os ativos indica como os ativos de uma empresa são lucrativos na geração de receita. É calculado dividindo-se o lucro líquido pelo total de ativos médios.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. em ativos de empresas na Setor Health Care em NASDAQ em comparação com DermTech

O que DermTech faz?

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Empresas com ret. em ativos semelhantes a DermTech